ANNOUNCEMENTS

SECOND INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
CURRENT STATUS AND PROSPECTS

The Second International Conference on Malignant Lymphoma will be held at the Palazzo dei Congressi, Lugano (Switzerland), June 13 through June 16, 1984.

This conference will deal with all important approaches in the diagnosis and treatment of Hodgkin’s and Non-Hodgkin’s lymphoma in children and adults.

Most lectures will be given by invited speakers. Selected controversial issues will be discussed by panels of leading experts. The program will include free presentations and a poster session. The deadline for receipt of abstracts is January 15th, 1984. For abstract forms and further information, please contact:

F. Cavalli, M.D.
Head, Division of Oncology
Ospedale San Giovanni
6500 BELLINZONA, Switzerland

HEMOCHROMATOSIS RESEARCH FOUNDATION

The Hemochromatosis Research Foundation, Inc. was formed to promote awareness that hereditary hemochromatosis is a common genetic disorder rarely diagnosed before clinically manifest, to prevent the associated chronic diseases by earlier case finding, to form regional chapters and establish a national registry, and to solicit funds for prevalence studies and research. Interested physicians may contact:

M.A. Krikker, M.D.
P.O. Box 8569
Albany, N.Y. 12208

SOUTHERN BLOOD CLUB

D. A. Lipschitz, President
D. Sears, Secretary/Treasurer

Thursday, January 27, 1983, 5:00 P.M.
New Orleans Hilton

SYMPOSIUM ON PROSTAGLANDINS IN HEMATOLOGY

Pharmacology of Prostaglandins ......................................................... Dr. John Oats
Vanderbilt University School of Medicine, Nashville, Tennessee

Prostaglandins, Platelets, and the Vascular Endothelium ........................................ Dr. John Hoak
University of Iowa School of Medicine, Iowa City, Iowa

Prostaglandins and Cancer ................................................................. Dr. Paulette Mehta
University of Florida College of Medicine, Gainesville, Florida

Sponsored by the Upjohn Company
WILMOT CANCER RESEARCH FELLOWSHIPS

The University of Rochester School of Medicine offers research training to individuals with the M.D. degree and at least one year of postdoctoral experience. Research fellows can train for up to three years in any discipline relevant to the cause, diagnosis, treatment or prevention of cancer. Training is available in fields such as: endocrinology, experimental therapeutics, genetics, hematology, immunology, microbiology, molecular and cellular biology, pathology, and radiation oncology.

Stipends range from $27,000 to $30,000, depending on the number of years since the M.D. degree was achieved. There is also an annual allowance of $6,000 for other research costs.

For further information, contact:
Wilmot Cancer Research Fellowship Program
Box 706
University of Rochester School of Medicine & Dentistry
601 Elmwood Avenue
Rochester, N.Y. (USA) 14642

COOLEY’S ANEMIA FOUNDATION FELLOWSHIPS

The Cooley’s Anemia Foundation, Inc. will award two or more fellowships for the period of July 1, 1983 to June 30, 1984 to qualified young investigators for research in areas directly related to Cooley’s Anemia.

Each Fellowship will consist of a stipend of $15,000/year (and not more than 10% institutional indirect cost). The award will be for one year, renewable upon reapplication for an additional year.

The deadline for the receipt of applications is November 15, 1982. Application forms may be obtained from:
Executive Secretary
Cooley’s Anemia Foundation, Inc.
105 East 22nd Street
New York, N.Y. 10010
Grune & Stratton Journals

AMERICAN JOURNAL OF KIDNEY DISEASES
The Official Publication of the National Kidney Foundation

George A. Porter, editor
Bimonthly
U.S.: $40.00 per year
Foreign: $66.00 per year

T. B. Boulton, editor
Monthly
U.S.: $172.50 per year
Foreign: $172.50 per year

W. Peters, chairman of editorial board
Bimonthly
U.S.: $119.50 per year
Foreign: $119.50 per year

Paul A. Marks, editor
Monthly
U.S.: $84.00 per year
Foreign: $91.00 per year

J. D. Hood, editor
Quarterly
Institutions: $59.00 per year
Individuals: $29.50 per year

Fritz A. Freyhan, editor
Bimonthly
U.S.: $35.00 per year
Foreign: $59.00 per year

Stephen L. Gans, editor
Bimonthly
U.S.: $52.00 per year
Foreign: $56.00 per year

Victor Bloom, editor
Monthly
U.S.: $103.00 per year
Foreign: $103.00 per year

Lester Mann, editor
Quarterly
U.S.: $27.00 per year
Foreign: $29.00 per year

James B. Field, editor
Monthly
U.S.: $70.00 per year
Foreign: $74.00 per year

Edmund H. Sonnenblick, editor, and Michael Lesch, co-editor
Bimonthly
U.S.: $47.00 per volume of 6 issues
Foreign: $50.00 per volume

Ronald L. Katz, editor
Quarterly
U.S.: $34.00 per year
Foreign: $38.00 per year

John H. Talbott, editor
Quarterly
U.S.: $44.00 per volume of 4 issues
Foreign: $48.00 per volume

L. Robert Martin, editor
Quarterly
U.S.: $27.00 per year
Foreign: $29.00 per year

Peter A. Miescher and Ernst R. Jaffé, editors
Quarterly
U.S.: $42.00 per year
Foreign: $46.00 per year

Neil A. Kurtzman, editor
Quarterly
U.S.: $35.00 per year
Foreign: $39.00 per year

Leonard M. Freeman and M. Donald Blaufus, editors
Quarterly
U.S.: $43.00 per year
Foreign: $47.00 per year

John W. Yarbro, editor
Quarterly
U.S.: $43.00 per year
Foreign: $46.00 per year

Thomas K. Oliver, Jr. and Thomas H. Kirschbaum, editors
Quarterly
U.S.: $37.00 per year
Foreign: $39.00 per year

Benjamin Felser, editor
Quarterly
U.S.: $46.00 per year
Foreign: $49.00 per year

Howard W. Raymond and William J. Zwiebel, editors
Quarterly
U.S.: $30.00 per year
Foreign: $33.00 per year

TRANSLANTATION PROCEEDINGS
An Official Publication of the Transplantation Society
The Japan Society for Transplantation

Felix T. Rasaporte, editor
Quarterly
U.S.: $35.00 per year
Foreign: $58.00 per year

Robert N. McClelland, editor
Monthly
U.S.: $85.00
Foreign: $99.00

Devon H. Char, editor
Monthly
U.S.: $85.00
Foreign: $99.00

AUDIOLoGY: JOURNAL FOR CONTINUING EDUCATION

Larry J. Bradford and Frederick N. Martin, editors
Monthly
U.S.: $35.00
Foreign: $39.00

Larry J. Bradford and Robert T. Wert, editors
Monthly
U.S.: $35.00
Foreign: $39.00

Michael Bender, editor
Monthly
U.S.: $35.00
Foreign: $39.00
American Society of Hematology  
Twenty-Fourth Annual Meeting  
Washington, D.C.  
December 4-7, 1982  
SUMMARY OF PROGRAM  

Saturday, December 4  
Morning:  
Education Program  
Acute Leukemia  
Hodgkin’s/NHL  
Bone Marrow Transplantation  
Chronic Leukemias  
Transfusion Therapy  
Pediatric Hematology  
Thrombosis & Acute Antithrombocytic Therapy  
Advances in Laboratory Hematology  
ABC’s of Molecular Genetics  
Drug & Immune Related Disorders  
Cytogenetics in Hematology  
Myeloma  
Clinical Application of Immune Markers  
Acquired Inhibitors & Acquired Hemostatic Failure  
Advances in Educational Methods  
Afternoon:  
Education Program  
Acute Leukemia  
Hodgkin’s/NHL  
Bone Marrow Transplantation  
Chronic Leukemias  
Transfusion Therapy  
Pediatric Hematology  
Thrombosis & Acute Antithrombocytic Therapy  
Advances in Laboratory Hematology  
ABC’s of Molecular Genetics  
Cytogenetics in Hematology  
Myeloma  
Myelodysplastic Syndrome  
Myeloma  
Acquired Inhibitors & Acquired Hemostatic Failure  
Scientific Subcommittee Symposia  
Hemoglobin—Red Cell  
Immunohematology  
Leukocyte Physiology  
Pediatric Hematology  
Forum on the Practice of Hematology  
Evening:  
Welcome Reception  

Sunday, December 5  
Morning:  
Education Program  
Acute Leukemia  
Hodgkin’s/NHL  
Bone Marrow Transplantation  
Chronic Leukemias  
Transfusion Therapy  
(Continued on following page)
Thrombosis & Acute Antithrombocytic Therapy
Advances in Laboratory Hematology
ABC's of Molecular Genetics
Drug & Immune Related Disorders
Cytogenetics in Hematology
Myelodysplastic Syndrome
Myeloma
Clinical Application of Immune Markers
Acquired Inhibitors & Acquired Hemostatic Failure
Advances in Educational Methods
Scientific Subcommittee Symposia
  Erythropoietin & Cell Proliferation
  Hemostasis
  Neoplasia
  Nutritional Anemias
Afternoon: First Business Meeting
  President's Report to the Society
  Stratton Lecture—E.A. McCulloch (“Stem Cells in Normal and Leukemic Hemopoiesis”)
  Plenary Session

Monday, December 6
Morning: Simultaneous Scientific Sessions
  Scientific Poster Session
Afternoon: Simultaneous Scientific Sessions
  Scientific Poster Session

Tuesday, December 7
Morning: Presidential Symposium—("From DNA, Gene, and Chromosome to Hematologic Disease")
  General Business Meeting
Afternoon: Simultaneous Scientific Sessions
INTERNATIONAL LABORATORY OPPORTUNITIES

SAUDI ARABIA

The best ... the philosophy, attitude and service of the King Faisal Specialist Hospital and Research Centre in Riyadh, the capital of Saudi Arabia. Managed by the Hospital Corporation of America Group, this modern 400-bed regional specialty and referral centre has exceptional employment opportunities for qualified laboratory personnel.

SUPERVISOR—COAGULATION

Will supervise and coordinate the activities of the coagulation subsection of Hematology. Qualified candidates must have a BS/MT, be a registered Medical Technologist and have a minimum of 5 years experience working in a coagulation section of an acute care hospital laboratory.

MEDICAL TECHNOLOGISTS—
HEMA/COAG/HLA

Qualified candidates must have a BS/MT, be MT(ASCP) registered and have a minimum of three (3) years experience as a medical technologist in an acute care hospital laboratory, the most current year in the specialty area. (Contracts for Med Techs are single status only.)

Commitments are for 24 months. Compensation and benefits are excellent and include: free furnished housing; air transportation; 30 days paid annual leave; bonus pay and more.

The excitement of a foreign assignment ... working in a challenging, sophisticated environment ... the experience of living in a multicultural community ... and the opportunities to travel to new and unusual places. A whole new lifestyle waiting to be explored! If you meet the stated qualifications and wish to become a member of this dynamic, multinational health care team, please send your resume to: Steven H. Ludlam, Senior International Representative, Hospital Corporation of America—International Division, P.O. Box 550, Nashville, TN 37202. An Equal Opportunity Employer.

HCA International Division
The Department of Pediatrics and Human Development has a position for a second faculty member in the area of Hematology/Oncology.

An active clinical service, a multi-disciplinary research group and a school involved in innovative medical education combine to offer faculty members all the elements of an excellent career. Appointment and salary commensurate with education and experience. MSU is an affirmative action/equal opportunity employer.

Contact: William B. Weil, Jr., M.D., Chairman Hematology Search Committee, Life Sciences Bldg., B240 Michigan State University, East Lansing, MI 48824-1317.

FACULTY POSITION, DIVISION OF HEMATOLOGY—ASSISTANT OR ASSOCIATE PROFESSOR OF MEDICINE. Hematologists with clinical and basic interests in coagulation with qualifications to direct a Comprehensive Hemophilia Diagnostic and Treatment Cancer. The position also includes limited responsibilities for the Clinical Coagulation Consult Service and Clinical Coagulation Laboratory. Research opportunities include basic and clinical research in hemorrhagic and thrombotic disorders. Minimum requirements are an M.D. degree, board certification in Internal Medicine, board eligibility in hematology, and significant experience in hemophilia care and clinical coagulation.

The University of North Carolina is an Equal Opportunity/Affirmative Action Employer. We are keenly interested in attracting outstanding women and/or minority faculty members to this department. Please send your curriculum vitae and a covering letter in which you state your field of research interest and references to Gilbert C. White, II, M.D. Division of Hematology 417 Burnett-Womack Clinical Sciences Building University of North Carolina School of Medicine Chapel Hill, NC 27414.

3RD INTERNATIONAL SYMPOSIUM ON THERAPY OF ACUTE LEUKEMIAS
ROME, ITALY DECEMBER 11, 12, 13, 14, 1982

The Third International Symposium on Therapy of Acute Leukemias will be held in Rome, Italy on December 11, 12, 13, 14, 1982 at the Congress Centre of the Hotel Hilton. The meeting will emphasize the most important issues concerning biology, clinic and therapy of acute leukemias. Registration fee Lit. 250.00 by cheque made payable to C.O.C.I.T.L.A.-Roma and sent to Organizing Secretariat. Deadline for presentation of abstracts: September 30, 1982. For further information please contact:

Organizing Secretariat
Franco Mandelli, M.D.
Cattedra di Ematologia
Via Chieti, 7
00161 Roma, Italy
Phone: 06/86.75.79

ADJUVANT THERAPY OF CANCER III
Edited by SYDNEY E. SALMON, M.D., and STEPHEN E. JONES, M.D.

Containing 60 provocative and competitively selected papers, this volume presents the proceedings of the Third International Conference on Adjuvant Therapy of Cancer, held in Tucson, Arizona, March 18-21, 1981. Internationally recognized experts in cancer therapy discuss data that is far more mature than it has been in the past, and share the highly positive results that have become available, particularly in breast cancer. In addition, they describe new leads that have been tested in head and neck cancer and other areas. Clinical trial presentations include new concepts relating to drug resistance mechanisms and the applications of in vitro chemosensitivity testing and prediction of response. Sections cover Biology and Therapeutic Approaches to Adjuvant Therapy of Cancer, Hematologic Malignancies, Gynecologic Cancer and Genitourinary Tumors, Melanoma and Sarcoma, Lung Cancer, Breast Cancer, and Gastrointestinal Tumors.

1981, 608 pp., $29.50
ISBN: 0-8089-1407-3; Order Code: 793748

Grune&Stratton
A Subsidiary of Harcourt Brace Jovanovich, Publishers
111 FIFTH AVENUE, NEW YORK, N.Y. 10003

Send payment with order and save postage and handling.
Prices are in U.S. dollars and are subject to change without notice.
American Red Cross

Directors for Blood Centers

American Red Cross Blood Service seeks physicians with blood banking and hematology training and experience, to serve as directors of regional blood centers. These positions offer an opportunity of medical and administrative leadership in providing blood supply throughout the United States, and to participate in education/research programs. Please forward C.V. to Alfred J. Katz, M.D., Executive Director, American Red Cross, Blood Services, 1730 E St., N.W., Washington, D.C. 20006. Equal Opportunity Employer. M/F.

THE DIVISION OF HEMATOLOGY, STANFORD UNIVERSITY SCHOOL OF MEDICINE, invites applications for two positions at the rank of Assistant Professor or Associate Professor.

Both positions require training and expertise in general internal medicine and in clinical hematology although board certification is not a requirement. Both positions will involve clinical work and clinical teaching in general internal medicine and hematology.

One position will require substantial clinical involvement and skills in the management of hematologic malignancies because the faculty member will oversee the activities of Stanford’s Compromised Host Unit. In addition, Stanford plans to start a bone marrow transplant program and this faculty member will have responsibilities and opportunities in the area of marrow transplantation. The faculty member will also be expected to engage in an investigative program which could be a laboratory program or a rigorous clinical investigation program.

The second position will require considerably less direct clinical involvement and the individual will be expected to develop an independent, self-sustaining, funded laboratory research program in an area relating broadly to the entire field of hematology. Candidates for this appointment should have already demonstrated substantial independent research productivity.

Applicants should send a curriculum vitae, a brief statement of their research interests and two references to:

Stanley L. Schrier, M.D., Chief
Division of Hematology
Stanford University School of Medicine
Stanford, CA, 94305

Stanford University is an equal opportunity employer and welcomes nominations of women and minority group members and applications from them.

POSTDOCTORAL FELLOWS IN BLOOD BANK SCIENCES:

A combined regional blood center and medical school hospital program designed for physician interested in a career as a hospital-based or regional blood bank director. Opportunities for basic and applied research in transfusion therapy, transplantation immunology, immunohematology and hemostasis are available.

Trainees will participate in teaching activities and will gain experience in medical and administrative aspects of blood banking. Clinical rotations on a hematology/oncology service can be arranged. Board certification or eligibility in hematology/oncology or clinical pathology desirable, but not essential. Positions available starting July 1, 1983.

Send C.V. to: Richard H. Aster, M.D., President. The Blood Center Of Southeastern Wisconsin, Inc. 1701 West Wisconsin Ave., Milwaukee, WI 53233.
Vascular Occlusion: Epidemiological, Pathophysiological and Therapeutic Aspects
edited by M. Tesi and J.A. Dormandy
July/August 1981, xii + 474pp., £28.80 (UK only) / $69.50, 0.12.685380.0

The papers collected in this volume were presented at the First International Colloquy of Angiology in Florence during October, 1979. They have been selected to ensure that the most recent advances in all aspects of angiology have been covered. The work described here represents the most significant and up-to-date research, much of which has not been published previously.

Genetic Engineering 2
edited by Robert Williamson
July/August 1981, xii + 204pp., £9.80 (UK only)/$24.00 (Paper), 0.12.270302.2

Contents

Iron in Biochemistry and Medicine
edited by A. Jacobs and M. Worwood
December 1980, xiv + 706pp., £41.00 (UK only) / $98.50, 0.12.378980.X

Iron in Biochemistry and Medicine II continues the approach of the first volume in providing a wide ranging scientific review of the biological aspects of iron metabolism. It provides a wealth of information about iron in man, animals and micro-organisms and highlights the relevance of biochemical knowledge to the study of clinical disorders.

Proceedings of the Serono Symposia Volume 38
Thymus, Thymic Hormones and T Lymphocytes
F. Aiuti and H. Wigzell
October 1980, x + 446pp., £25.00 (UK only) / $57.50, 0.12.046450.0

In recent years there has been a growing awareness of the important part which the thymus, its hormones and the T-dependent lymphocytes play in certain aspects of immunology. This book reports the proceedings of a symposium at which the most recent research in this area was presented and discussed. Also included are details of investigations into certain cell types which appear to be under the influence of the thymus, such as natural killer cells.
"An excellent source of current thinking in hematology" —JAMA
(From a review of the series)

Progress in Hematology

VOLUME XII

Edited by ELMER B. BROWN, M.D.

Progress in Hematology is a series of authoritative volumes that afford the practicing clinician clear and concise reviews of topics of current interest in hematology. Each volume is designed to provide a broad perspective rather than minute details of specialty problems.

The first volume in the series was published in 1956. Subsequent volumes have recorded the period of most rapid growth of biomedical science. Throughout the years the editors have tried to maintain a balance between the review that emphasizes basic, sometimes esoteric, experimental topics and the more practical clinical accounts. With the rapid explosion of knowledge, the proliferation of the written word, and the ultra-specialization within the disciplines encompassed by hematology, the need for comprehensive, interpretative reviews will increase.

Order Code: 790702

CONTENTS:
Geoffrey Herzig, Autologous Marrow Transplantation in Cancer Therapy
Arthur Bank, Globin Gene Structure in Disorders of Hemoglobin
James Kushner, Corwin Edwards and Mark Skolnick, Hereditary Hemochromatosis: Contributions of Genetic Analyses
Jack Hirsh and Russell Hull, Advances and Controversies in the Diagnosis, Prevention, and Treatment of Venous Thromboembolism
Louis M. Aledort and Scott H. Goodnight, Hemophilia Treatment—Its Relationship to Blood Products
Carol K. Kasper, Management of Inhibitors of Factor VIII
Stuart Schlossman et al., Diagnosis and Treatment of Human Leukemias Utilizing Monoclonal Antibodies
Alvin Mauer and Paul Bowman, The Role of Cell Markers in the Management of Leukemia
Neal Young, Aplastic Anemia: Research Themes, Clinical Issues
Lowell Schnipper, The Epstein-Barr Virus and Lymphoproliferative Disorders: New Concepts and Directions
Ernest C. Borden and L. Andrew Ball, Interferons: Biochemical, Cell Growth, Inhibitory, and Immunological Effects

Future volumes in PROGRESS IN HEMATOLOGY are now available on a Continuation Order basis. Your Continuation Order authorizes us to ship and bill each future volume in the series automatically, immediately upon publication. This order will remain in effect until cancelled. Specify the volume number or title with which your order is to begin.

Grune & Stratton
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco
111 FIFTH AVENUE, NEW YORK, N.Y. 10003

PN 153017
**Factor Deficient Human Plasma**

- **Substrate Quality**
- **Stable**
- **Fresh Frozen**
- **Mono-Specific**

(Partial) Price List (F.O.B. Overland Park, Kansas)

<table>
<thead>
<tr>
<th>Coagulation Deficiency</th>
<th>In 5 ml Vials</th>
<th>In Bags</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor XI, XII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ml</td>
<td>$ 60.00</td>
<td>250 ml $4.50 per ml</td>
</tr>
<tr>
<td>25 ml</td>
<td>145.00</td>
<td>500 ml 4.25 per ml</td>
</tr>
<tr>
<td>50 ml</td>
<td>280.00</td>
<td>1000 ml Special Quote</td>
</tr>
<tr>
<td>100 ml</td>
<td>540.00</td>
<td></td>
</tr>
<tr>
<td>Factor VIII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ml</td>
<td>$ 32.50</td>
<td>250 ml $1.80 per ml</td>
</tr>
<tr>
<td>25 ml</td>
<td>75.00</td>
<td>500 ml 1.65 per ml</td>
</tr>
<tr>
<td>50 ml</td>
<td>137.50</td>
<td>1000 ml Special Quote</td>
</tr>
<tr>
<td>100 ml</td>
<td>250.00</td>
<td></td>
</tr>
</tbody>
</table>

- All shipments are packed with dry ice in styrofoam boxes. (Handling Charge for orders under $250.00).
- Shipments within the United States are delivered within 24 hours.
- Plasma can be aliquoted to smaller amounts (1, 2, 3, 4 ml) at an additional charge of $.50 per vial.
- Special discount prices upon request for standing orders or large volumes.

Also available — • FACTORS I, II, V, VII, IX, X, XIII • FACTORS VIII or IX with inhibitor

Prekallikrein Deficient • Von Willebrand • Passovoy Trait • Kininogen Deficient

Normal Reference Human Plasma

For Complete Details — Write or Call

GEORGE KING BIO-MEDICAL, INC.,
9209 West 110 Street, Overland Park, KS 66210
Toll free 1-800-255-5108 Phone (913) 649-2272

---

**INDEX TO ADVERTISERS**

**OCTOBER 1982**

ACADEMIC PRESS PUBLISHERS ........................................ xxiii, xxvii, xxxvii
ARMOUR PHARMACEUTICALS ........................................... x, xi
AUTO-SYRINGE, INC. .................................................. xxxiv
BIO/DATA CORPORATION ............................................ xxi
COULTER ELECTRONICS, INC. ...................................... 2C, iii
GEORGE KING BIO-MEDICAL, INC. ......................................
GRUNE & STRATTON PUBLISHERS ................................... xviii, xxvi, xxxvi, xxxix
IVES LABORATORIES ...................................................
JCI CLINICAL RESEARCH CORPORATION ............................ xiii
JANSSEN PHARMACEUTICA ........................................... xxv, xxvi
JEWETT REFRIGERATOR CO., INC. ...................................
JOHNSON REPRINT CORPORATION .................................. xxviii
LEDERLE LABORATORIES ............................................ 3C
MILES LABORATORIES, RESEARCH PRODUCTS DIVISION ....... xxv
C. V. MOSBY CO. PUBLISHERS .................................... xvii
RESEARCH INDUSTRIES CORPORATION ............................ xxix

A. H. ROBINS COMPANY .................................................. xiv, xvi
TERUMO CORPORATION ........................................... xix–xxii
WELLCOME DIAGNOSTICS DIVISION OF BURROUGHS ...........
WELLCOME CO. .................................................. iv

**CLASSIFIED**

AMERICAN RED CROSS
Directors for Blood Centers ......................................... xxxvii
BLOOD CENTER
Postdoctoral Fellows in Blood Bank Sciences ................... xxxvii
C.O.C.I.T.L.A. ROMA
3rd International Symposium on Therapy of Acute Leukemias 

HOSPITAL CORPORATION OF AMERICAN
INTERNATIONAL DIVISION
International Laboratory Opportunities Saudi Arabia ....... xxxv
STANFORD UNIVERSITY SCHOOL OF MEDICINE
Two positions—Division of Hematology ....................... xxxvii
MICHIGAN STATE UNIVERSITY
Second Faculty Member in the area of Hematology/Oncology 

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Faculty Position ............................................. xxxvi
Whenever a folic acid antagonist is administered, Leucovorin Calcium should be readily available to help offset possible toxicity.

Exclusively from Lederle Laboratories, Leucovorin Calcium is considered to be highly effective in counteracting the life-threatening effects of possible overdosage of a folic acid antagonist.

**LEUCOVORIN CALCIUM INJECTION**

**DESCRIPTION** Each 1 ml ampul of Leucovorin Calcium Lederle contains Leucovorin 3 mg as the calcium salt which is the form preferred for intramuscular injection. Preservative: benzyl alcohol 0.9% w/v. The inactive ingredients are sodium chloride 0.56% w/v. Water for Injection qs 100% and sodium hydroxide or hydrochloric acid is used to adjust the pH to approximately 7.7.

Each 50mg vial of Leucovorin Calcium cryodesiccated powder when reconstituted with 5 ml of sterile diluent contains Leucovorin 10 mg per ml as the calcium salt which is the form preferred for intramuscular injection. Contains no preservative. Dilute only with Bacteriostatic Water for injection USP which contains benzyl alcohol. The inactive ingredients are sodium chloride 40mg/vial, and sodium hydroxide or hydrochloric acid qs to pH approximately 8.1. When reconstituted as directed, the resulting solution must be used within 7 days. If the product is reconstituted with Water for Injection USP use immediately.

**ACTIONS** Leucovorin (folinic acid) is the formyl derivative and active form of folic acid. Leucovorin Calcium is useful clinically in circumventing the action of folic acid antagonists. (See Warnings.) (b) In the treatment of the megaloblastic anemias due to sprue, nutritional deficiency, pregnancy, and infancy when oral therapy is not feasible.

**INDICATIONS** Indicated (a) to diminish the toxicity and counteract the effect of inadvertent administered overdosages of folic acid antagonists. (See Warnings). (b) in the treatment of the megaloblastic anemias due to sprue, nutritional deficiency, pregnancy, and infancy when oral therapy is not feasible.

**CONTRAINDICATIONS** Not to be administered for the treatment of pernicious anemia or other megaloblastic anemias where Vitamin B12 is deficient.

**WARNINGS** Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to lack of vitamin B12. A hematologic remission may occur while neurologic manifestations remain progressive.

In the treatment of overdosage of folic acid antagonists, Leucovorin must be administered within 1 hour, if possible; and is usually ineffective if administered after a delay of 4 hours.

**PRECAUTIONS** In the presence of pernicious anemia a hematologic remission may occur while neurologic manifestations remain progressive.

**ADVERSE REACTIONS** Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

**DOSEAGE** Megaloblastic anemia. No more than or up to 1 mg daily. There is no evidence that intramuscular doses greater than 1 mg daily have greater efficacy than those of 1 mg.

For the treatment of overdosage of folinic acid antagonists. To be given in amounts equal to the weight of the antagonist given.

**HOW SUPPLIED** 6-1 ml Ampuls—Product Number 4004 50 mg Vial of Cryodesiccated powder—Product Number 5330

**LEDERLE LABORATORIES**
A Division of American Cyanamid Company Wayne, New Jersey 07470 © 1982 Lederle Laboratories
INTRODUCING
A new dimension in coagulation testing

General Diagnostics
Division of Warner-Lambert Company
Nutley, N.J.

COAG-A-MATE® 8.2
Doubles throughput on all routine tests without wasting reagents or disposables